Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Tanta University
Age
18–60
Sex
FEMALE
Healthy volunteers
Accepted
You may be eligible if
Age ≥18 years old.
Chemo-naïve patients with biopsy confirmed diagnosis of breast cancer and with stage I-III breast cancer according to the American Joint Committee on Cancer (TNM staging system of breast cancer).
Patients intended to receive at least 4 cycles of doxorubicin or more.
Patients with performance status \<2 according to Eastern Cooperative Oncology Group (ECOG) score.
Patients with adequate liver function and adequate renal function.
Signed informed consent to participate in the study.
You may not be if
Age \<18 years old and \>65 years old.
Women with history of breast cancer.
Formerly treated with DOX.
Patients with a known hypersensitivity to any of the used drugs.
Treatment with blood thinners for 6 months prior to the screening.
Treatment with NSAIDS like ketorolac,ibuprofen.
Patients taking any other cardioprotective medications.
Pregnancy and breast feeding.
Alcohol abuse.
Creatine Clearance \< 50 mL/min.
History of heart failure or LVEF \<50%.
Presence of any cardiac-related conditions such as angina pectoris, valvular disease, uncontrolled systemic hypertension, coronary heart disease, and cardiac surgery within the last 3 months.
Clareo Health | Clinical Study to Evaluate The Cardioprotective Effect of Pentoxifylline Against Doxorubicin Induced Cardiotoxicity in Breast Cancer Patients
